Commensal bacterial metabolites may strengthen the effect of anti-IL6 treatment for COVID-19
- PMID: 34601117
- PMCID: PMC8482650
- DOI: 10.1016/j.clim.2021.108870
Commensal bacterial metabolites may strengthen the effect of anti-IL6 treatment for COVID-19
Keywords: Butyrate; COVID-19; Regulatory T cells; Tocilizumab.
Comment on
-
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.Clin Immunol. 2021 Feb;223:108631. doi: 10.1016/j.clim.2020.108631. Epub 2020 Nov 12. Clin Immunol. 2021. PMID: 33189888 Free PMC article.
References
-
- Bultman S.J. Bacterial butyrate prevents atherosclerosis. Nat. Microbiol. 2018;3:1332–1333. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical